Author

B. Savoldo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

G. Dotti· 3 shared E. Landoni· 2 shared A. Battu· 1 shared A. N. Jambor· 1 shared A. Ottaviani· 1 shared A. Venditti· 1 shared A. Williams· 1 shared B. Chick· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

G. Dotti

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Atlas-Guided Discovery of Transcription Factors for T Cell Programming

H. K. Chung, C. Liu, A. Battu, A. N. Jambor, B. M. Pratt, F. Xie, B. P. Riesenberg, E. Casillas, M. Sun, E. Landoni, Y. Li, Q. Ye, D. Joo, J. Green, Z. Syed, , S. M. Kaech

The paper identifies transcription factors driving distinct CD8+ T cell states and shows their impact on tumor control and immunotherapy.

bioRxiv · Jan 3, 2023Immunology

Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells.

S. h. Lee, Y. Hao, T. Gui, G. Dotti, B. Savoldo, F. Zou, T. Kafri

This study shows that murine VL30 retrotransposons can be inadvertently transferred to CAR-T cells via γ-retroviral vectors, raising biosafety concerns.

bioRxiv · Feb 1, 2022Microbiology

ELIMINATION OF EGFR-OVEREXPRESSING CANCER CELLS BY CD32 CHIMERIC RECEPTOR T CELLS IN COMBINATION WITH CETUXIMAB OR PANITUMUMAB

S. Caratelli, R. Arriga, T. Sconocchia, A. Ottaviani, G. Lanzilli, D. Pastore, C. Cenciarelli, A. Venditti, M. I. Del Principe, D. Lauro, E. Landoni, H. Du, B. Savoldo, S. Ferrone, G. Dotti, G. Sconocchia

This study shows CD32131R-CR T cells can eliminate EGFR-overexpressing cancer cells when combined with cetuximab or panitumumab, outperforming CD16158F-CR T cells.

bioRxiv · Mar 18, 2019 · PreprintImmunology